223 related articles for article (PubMed ID: 25999488)
21. Stimulating antibiotic development.
Tillotson G
Lancet Infect Dis; 2010 Jan; 10(1):2-3. PubMed ID: 20129141
[No Abstract] [Full Text] [Related]
22. [Open innovation: public-private partnerships in pharmaceutical R&D].
Uchibayashi N
Nihon Yakurigaku Zasshi; 2013 Jul; 142(1):32-8. PubMed ID: 23842226
[No Abstract] [Full Text] [Related]
23. Partnering for therapeutics discovery.
Colvis CM; Devaney S; Brady LS; Hudson KL
Clin Pharmacol Ther; 2013 Jan; 93(1):24-5. PubMed ID: 23187876
[No Abstract] [Full Text] [Related]
24. Biomedicine. Pharma firms push for sharing of cancer trial data.
Bhattacharjee Y
Science; 2012 Oct; 338(6103):29. PubMed ID: 23042862
[No Abstract] [Full Text] [Related]
25. Report calls for $2bn global fund to kickstart antibiotic development.
Wise J
BMJ; 2015 May; 350():h2635. PubMed ID: 25975228
[No Abstract] [Full Text] [Related]
26. European lead factory opens for business.
Mullard A
Nat Rev Drug Discov; 2013 Mar; 12(3):173-5. PubMed ID: 23449292
[No Abstract] [Full Text] [Related]
27. [Open innovation and licensing in the pharmaceutical industry].
Yamasaki M
Nihon Yakurigaku Zasshi; 2013 Jul; 142(1):28-31. PubMed ID: 23842225
[No Abstract] [Full Text] [Related]
28. [Open innovation for Japanese pharmaceutical companies].
Hoshino T
Nihon Yakurigaku Zasshi; 2013 Oct; 142(4):184-9. PubMed ID: 24107523
[No Abstract] [Full Text] [Related]
29. The current state of drug discovery and what it might take to improve drug discovery outcomes and approval successes.
Turner MJ
Drug Discov Today; 2015 Aug; 20(8):917-9. PubMed ID: 26100736
[No Abstract] [Full Text] [Related]
30. Pay drug companies $1bn for each new antibiotic, says report.
Owen J
BMJ; 2016 May; 353():i2863. PubMed ID: 27198868
[No Abstract] [Full Text] [Related]
31. R&D: Antibiotic partners promote discovery.
Bakken JS
Nature; 2016 Sep; 537(7619):167. PubMed ID: 27604939
[No Abstract] [Full Text] [Related]
32. Antibiotics: a shot in the arm.
Leeb M
Nature; 2004 Oct; 431(7011):892-3. PubMed ID: 15496888
[No Abstract] [Full Text] [Related]
33. Open innovation: share or die..
Talaga P
Drug Discov Today; 2009 Nov; 14(21-22):1003-5. PubMed ID: 19778629
[No Abstract] [Full Text] [Related]
34. Ian Tomlinson.
Tomlinson I
Nat Rev Drug Discov; 2016 Mar; 15(3):154. PubMed ID: 26893183
[No Abstract] [Full Text] [Related]
35. Q&A: Bernard Munos.
Bender E
Nature; 2016 May; 533(7602):S59. PubMed ID: 27167392
[No Abstract] [Full Text] [Related]
36. Antibiotic development - economic, regulatory and societal challenges.
Årdal C; Balasegaram M; Laxminarayan R; McAdams D; Outterson K; Rex JH; Sumpradit N
Nat Rev Microbiol; 2020 May; 18(5):267-274. PubMed ID: 31745330
[No Abstract] [Full Text] [Related]
37. Discovery research: the scientific challenge of finding new antibiotics.
Livermore DM;
J Antimicrob Chemother; 2011 Sep; 66(9):1941-4. PubMed ID: 21700626
[TBL] [Abstract][Full Text] [Related]
38. Michael Rosenblatt.
Nat Rev Drug Discov; 2016 Sep; 15(10):672. PubMed ID: 27681789
[No Abstract] [Full Text] [Related]
39. Regulatory Consequences of "Brexit" for the Development of Medicinal Products.
Jackson EL; Feldschreiber P; Breckenridge A
Clin Pharmacol Ther; 2017 Aug; 102(2):183-184. PubMed ID: 28555841
[TBL] [Abstract][Full Text] [Related]
40. Biopharma deal-making in 2016.
Micklus A; Muntner S
Nat Rev Drug Discov; 2017 Mar; 16(3):161-162. PubMed ID: 28209988
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
